Psychedelics

“No one alive is responsible for what happened hundreds or thousands of years ago, but we are part of a continuum.” – Zoe Helene

Dr. Markus Roggen is the founder of Complex Biotech Discovery Ventures, a private research center for cannabis science and collaborator for academic research.

A proposal in Maine is seeking to legalize psilocybin mushroom therapy for anyone aged 21 or older.

The California Senate Public Safety Committee has advanced a psychedelics decriminalization measure.

Researchers at the Imperial College London say that any psychological benefits of microdosing LSD — which are frequently described, at least anecdotally — are likely caused by the placebo effect.

A Missouri lawmaker has proposed expanding the state’s Right to Try law to include psychedelic substances such as psilocybin, MDMA, LSD, mescaline, ibogaine, and DMT.

As an entrepreneur, Michael “Zappy” Zapolin is known as a pioneer in the domain name industry. As a filmmaker, he has emerged as a powerful advocate for the legalization and normalization of psychedelics.

New Jersey Gov. Phil Murphy has signed legislation reducing the penalties for the possession of psilocybin mushrooms from a third-degree crime to a disorderly person offense.

The UK has approved trials to assess the safety — and eventually efficacy — of DMT as a potential treatment for depression.

Lawmakers in New Jersey’s Assembly Judiciary Committee have advanced a bill that would lower possession penalties for psilocybin mushrooms from a potential 5-year prison sentence to a maximum $1,000 fine and six months in jail.

A recent study found that psilocybin therapy offered “more than four times greater” relief than traditional antidepressant medications.

With the landmark passage of Measures 109 and 110, Oregon voters have opted to decriminalize drugs and legalize medicinal psilocybin.

Voters in Washington, D.C. have overwhelmingly approved Initiative 81 to decriminalize psychedelic plants.

Across the U.S. today, voters from Montana to New Jersey will consider a series of ballot initiatives that could represent yet another dramatic shift for the country away from our archaic cannabis and drug policies.

The Ann Arbor, Michigan City Council has unanimously passed a resolution to decriminalize naturally occurring psychedelics, including mushrooms and ayahuasca.

Oregon’s initiative to legalize the medicinal use of psilocybin has officially qualified for the November ballot.

The U.S. Defense Advanced Research Projects Agency is funding a medical health study into the therapeutic use of psychedelics such as ketamine and psilocybin.

The latest documentary from streaming platform Netflix features celebrity interviews and re-enactments of psychedelic experiences alongside real information about psychotropic medicines. Have a Good Trip: Adventures in Psychedelics is a wonderfully built look at your brain on drugs — but in a good way.

Separate campaigns to legalize psilocybin therapy and to decriminalize all illegal drugs have teamed up in Oregon to gather signatures.

The Dr. Bronners soap company announced it has contributed $1 million to the psilocybin therapy legalization campaign in Oregon.

In celebration of the 4/20 holiday this month, we are using the whole month of April to focus on courageous cannabis and drug policy pioneers. Today, on what would have been his 89th birthday, we celebrate Baba Ram Dass, who helped legitimize the psychedelic revolution of the 1960s and awaken the public to the immorality of prohibition.

New York City-based Mind Medicine announced it had partnered with the world-leading psychedelics pharmacology and clinical research laboratory at University Hospital Basel in Switzerland.

A Vermont state lawmaker has pitched the decriminalization of three psychedelic substances — psilocybin, ayahuasca, and peyote — as well as kratom.

Scientists have created a bacteria solution that exudes industrial quantities of psilocybin, the psychedelic compound in “magic mushrooms” that is being studied as a potentially groundbreaking treatment for depression and other mental health afflictions.